Henan Newland Pharmaceutical Co. Ltd. A (301277) — Capital Reinvestment Ratio
Henan Newland Pharmaceutical Co. Ltd. A (301277) has a Capital Reinvestment Ratio of 0.87x as of December 2025, meaning it reinvests 1% of its operating cash flow (CN¥116.94 Million) in capital expenditures (CN¥101.38 Million). See Henan Newland Pharmaceutical Co. Ltd. A balance sheet independence to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Henan Newland Pharmaceutical Co. Ltd. A Capital Reinvestment Ratio (2020–2025)
This chart tracks Henan Newland Pharmaceutical Co. Ltd. A's Capital Reinvestment Ratio across 6 annual periods. Check Henan Newland Pharmaceutical Co. Ltd. A investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Henan Newland Pharmaceutical Co. Ltd. A (2020–2025)
Year-by-year Capital Reinvestment Ratio for Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2025. For live market cap and broader valuation context, see Henan Newland Pharmaceutical Co. Ltd. A market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.87x | CN¥116.94 Million | CN¥101.38 Million | ▼ -0.8% |
| 2024 | 0.87x | CN¥126.76 Million | CN¥110.79 Million | ▲ +135.0% |
| 2023 | 0.37x | CN¥259.46 Million | CN¥96.51 Million | ▼ -58.5% |
| 2022 | 0.90x | CN¥82.85 Million | CN¥74.34 Million | ▲ +73.4% |
| 2021 | 0.52x | CN¥49.08 Million | CN¥25.40 Million | ▲ +46.0% |
| 2020 | 0.35x | CN¥47.86 Million | CN¥16.96 Million | — |